Therapeutic Drug Substitution Might Be Worth A Look For Part D, CBO Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
CBO report says there's not much more savings to be squeezed out of generic substitution, although there is room for more to be saved through therapeutic substitution.
You may also be interested in...
Boosting Therapeutic Substitution Rests With Physician Education, HHS Says
Issue brief by the Office of the Assistant Secretary for Planning and Evaluation cites cost-savings potential of increasing substitution of brand drugs with generics that are not therapeutically equivalent but carry the same indication.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.